Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 30.09.19
Views: 2826
Rating:

Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith

Dr Eleni Efstathiou (MD Anderson Cancer Center, Houston, USA), Prof Noel Clarke (The Christie NHS Foundation Trust, Manchester, UK), Dr Elena Castro (Spanish National Cancer Research Center, Madrid, Spain) and Prof Matthew Smith (Massachusetts General Hospital Cancer Center, Boston, USA) discuss the key developments presented at ESMO 2019 on targeted therapies in prostate cancer.

The panel discuss the latest data from the STAMPEDE trial and the use of docetaxel in high-volume disease versus low-volume disease in metastatic de-novo and hormone naïve prostate cancer.

Prof Smith also gives an overview of the STAMPEDE study and the recent developments presented from this trial at ESMO 2019.

The panel conclude by discussing the PROFOUND study, using olaparib in the treatment of patients with metastatic castration-resistant prostate cancer who harbour homologous recombination repair gene mutations. However, identifying these patients with DNA mismatch repair mutations, not just BRCA mutations remains a challenge.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

SIOG metastatic renal cell carcinoma


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation